Genscript Biotech Corporation (G51) — Strategic Asset Allocation Index
Genscript Biotech Corporation (G51) has a Strategic Asset Allocation Index of 32.9% as of June 2023. Strategic assets (PP&E of €686.45 Million plus long-term investments of €-) total €686.45 Million, measured against net assets of €2.09 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check how resilient are Genscript Biotech Corporation's assets to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Genscript Biotech Corporation Strategic Asset Allocation Index (2016–2021)
This chart shows how Genscript Biotech Corporation's Strategic Asset Allocation Index has evolved across 6 annual periods from 2016 to 2021. As of June 2023, the index stands at 32.9%, representing strategic assets of €686.45 Million against net assets of €2.09 Billion EUR. See G51 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Genscript Biotech Corporation (2016–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Genscript Biotech Corporation from 2016 to 2021, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see G51 market cap overview.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 45.7% | €499.03 Million | €499.03 Million | €- | €1.09 Billion | ▼ -0.8 pp |
| 2020 | 46.5% | €379.23 Million | €379.23 Million | €- | €815.59 Million | ▼ -24.9 pp |
| 2019 | 71.3% | €265.63 Million | €265.63 Million | €- | €372.30 Million | ▲ +39.3 pp |
| 2018 | 32.0% | €158.01 Million | €158.01 Million | €- | €493.30 Million | ▼ -3.2 pp |
| 2017 | 35.3% | €80.51 Million | €80.51 Million | €- | €228.32 Million | ▲ +11.5 pp |
| 2016 | 23.8% | €43.73 Million | €43.73 Million | €- | €184.02 Million | — |